学术代表-云南(J12102)

上海汇伦江苏药业有限公司

Chinese pharmaceutical manufacturer established in December 2010 in Taizhou, Jiangsu as a wholly owned subsidiary of Shanghai Huilun Life Science and Technology (formerly Shanghai Huilun Biotechnology), which itself was founded in 2004 to research, manufacture and market high quality small molecule medicines. Concentrates on chemical drug development and production across oncology, cardiovascular, digestive and gynaecological treatment, and by 2023 had built active ingredient, lyophilised powder injection and oral solid dosage workshops to China's revised GMP standard with annual capacity of around 20 tonnes of active ingredients, 100 million tablets and one million lyophilised vials.